ABSTRACT
INTRODUCTION
Since ventriculoatrial shunts were widely used in the past, clinicians may be faced with patients having pulmonary hypertension due to ventriculoatrial shunt. In this case report, we presented a case with pulmonary hypertension after ventriculoatrial shunt implantation. Our aim is remind that patients with ventriculoatrial shunts have an increased risk of developing pulmonary hypertension, which can occur decades after shunt implantation.
CASE
A 30-years old, male patient was applied to an outside hospital complaining severe dyspnea last 2-3 days but gradually increasing since that is 6 months. Transthoracic echocardiography was performed to the patient and revealed that right cardiac chambers were wide and pulmonary artery pressure was high. His electrocardiography was showed right axis deviation and incomplete right bundle branch block. (Figure 1 ) The patient was referred to our clinic for further evaluation with suspect of an atrial septal defect. In history of the patient, ventriculoatrial shunt was performed to treat hydrocephalus which was occurred after a traffic accident. Transthoracic echocardiography revealed dilatation of right cardiac chambers and second degree tricuspid valve regurgitation. Pulmonary artery systolic pressure was 85 mmHg (70+15mmHg). (Figure 2 ) and there was a shunt catheter in the right atrium. Transesophageal echocardiography showed a patent foramen ovale but not atrial septal defect and doppler echo demonstrated flow across the interatrial septum in a right to left direction. Development of pulmonary hypertension was considered after ventriculoatrial shunt implantation. On pulmonary Tc-99m MAA (Macro Aggregated Albumin) perfusion scintigraphy, segmental and subsegmental perfusion defects were observed. These scintigraphy findings were reported as the most likely results of pulmonary thromboemboli. The patient was recommended to apply to the Brain Surgery Clinic and shunt was replaced to the ventriculoperitoneal shunt. Warfarin medication as anticoagulation therapy was given to the patient and discharged with recommendation of clinical follow-up .
DISCUSSION
Ventriculoatrial shunt implantation was first used for treatment of hydrocephalus in late 1940s (1) . After demonstrations of ventriculoatrial shunt implantation as an efficient and survive improving medication in treatment of hydrocephalus, it was widely used in 1950s. However, several ventriculoatrial shunt related complications were observed including shunt infections, infective endocarditis, septicemia, meningitis, arrhythmias, myocardial damage, obstruction of vena cava, intracardiac thrombus, pulmonary emboli and pulmonary hypertension in 1970s. Therefore, ventriculoatrial shunt implantations were mostly abandoned (2,3) and ventriculoperitoneal shunts were preferred to use because of their ease and lower level complications (4). Since ventriculoatrial shunts were widely implanted in the past, it is possible to be faced with these patients in clinics. Kluge et al. retrospectively evaluated 575 patients having pulmonary hypertension between 1999 and 2006, and reported findings of 6 patients with ventriculoatrial shunt (5). Mean age of these patients were 42.5+/-8.3 years, pulmonary arterial pressure was 53.3+/-14.9 mmHg and the median interval from shunt implantation to the diagnosis of pulmonary hypertension was 16.5 years. On ventilation perfusion scintigraphy, bilateral multiple perfusion defects were observed in all patients but pulmonary thromboembolism was observed in only two patients on pulmonary angiography and thorax CT.
Bonderman et al reported that ventriculoatrial shunts increased the likelihood of chronic thromboembolic pulmonary hypertension 13-fold (6) . Pathogenetic process underlying pulmonary hypertension in these patients remains unclear. Several mechanisms have been proposed, such as the presence of shunt infection causing the persistent activation of clotting factors with recurrent thromboembolism (5,7) or a reaction of the pulmonary endothelium to some yet undefined contents of cerebrospinal fluid, possibly brain thromboplastin (5). Seratonin is a component of the cerebrospinal fluid and its strong vasoconstrictor feature may have a critical role in severe pulmonary hypertension development (5) There is a long asymptomatic embolization period before development of severe pulmonary hypertension in most cases. In cases that were reported by Kluge et al., the mean period was 16.5 years for diagnosis of pulmonary hypertension from shunt implantation and the mean time from the first symptoms to diagnosis was 9.5 months (1.5-12 months). These periods were 15 years and 6 months in our case, respectively. A serious time lag between the first symptoms and diagnosis has critical importance in these cases. Probable reasons for such delays may be pulmonary hypertension cases are rarely seen in population and the lack of awareness that ventriculoatrial shunts cause pulmonary hypertension.
In summary, patients with ventriculoatrial shunts should be kept under careful evaluation for symptoms of progressive dyspnea on exertion because of having increased risk of pulmonary hypertension. After diagnosis, shunt should be removed and replaced with another type of shunt if necessary. These patients should receive lifelong anticoagulation adjusted to a target INR between 2 and 3. 
